Oscine Therapeutics IVS: Financial statements 2018
CVR: 38663062
Source: annual report 2018, Danish Business Authority
01/01/2018 – 31/12/2018
Oscine Therapeutics IVS (CVR 38663062) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK -1,415 and a net result of DKK -1,415. Equity in the 2018 report amounted to DKK 5,585. The solvency ratio was 77.5%.
- Gross Profit
- DKK -1,415
- Profit/Loss
- DKK -1,415
- Equity
- DKK 5,585
- Total Assets
- DKK 7,208
- Employees
- 0
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
Oscine Therapeutics IVS has published its interim report for the period May 24, 2017 to December 31, 2017.
As of March 22, 2018, Steven Alan Goldman is registered as chairman of Oscine Therapeutics IVS.
As of March 22, 2018, Christina Trojel-Hansen is registered as director of Oscine Therapeutics IVS.
As of March 22, 2018, Steven Alan Goldman has stepped down as director of Oscine Therapeutics IVS.
About Oscine Therapeutics IVS
Oscine Therapeutics IVS was a Danish company of the type Iværksætterselskab based in København N, founded in 2017. The company has been dissolved on 15 January 2020. The company was registered under the industry Forskning og eksperimentel udvikling indenfor bioteknologi. According to the 2018 annual report, the company had an average of 0 employees. In 2018, the company reported a gross profit of DKK -1,415 and a net result of DKK -1,415. Equity in the 2018 report amounted to DKK 5,585.
